BioMarin Pharmaceutical Inc. (BMRN) Initiates Phase 3 Trial for BMN 673 for the Treatment of Metastatic gBRCA Breast Cancer
10/31/2013 10:00:46 AM
SAN RAFAEL, Calif., Oct. 31, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has dosed the first patient in its Phase 3 program to evaluate BMN 673, its poly ADP-ribose polymerase (PARP) inhibitor, in the treatment of metastatic germline BRCA mutated breast cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by